Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B known ✓ | Q13370 | 3/20 | 0.32 |
| ▸ | PDE3A known ✓ | Q14432 | 3/20 | 0.32 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA known ✓ | P42336 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27870401 | 0.98 | KDM5B (0.35) | KDM5BPIM1PIM3PIM2SYK | |
| SCHEMBL15367185 | 0.82 | KDM5B (0.49) | KDM5BPIM1PIM3PIM2SYK | |
| Hydrochloric Acid SCHEMBL2693396 | 0.76 | KDM5B (0.46) | KDM5BPIM1AURKAAURKBTTK | |
| Hydrochloric Acid SCHEMBL15348732 | 0.76 | KDM5B (0.46) | KDM5BPIM1AURKAAURKBTTK | |
| SCHEMBL14858506 | 0.74 | KDM5B (0.47) | KDM5BPIM1AURKAAURKBTTK | |
| Hydrochloric Acid SCHEMBL2694026 | 0.71 | MAPK1 (0.34) | KDM5BPIM1 | |
| Hydrochloric Acid SCHEMBL2692840 | 0.70 | JAK2 (0.39) | KDM5B | |
| SCHEMBL27870423 | 0.69 | MAPK1 (0.42) | KDM5BPIM1PIM3PIM2 | |
| SCHEMBL28018702 | 0.69 | MAPK1 (0.34) | KDM5BPIM1 | |
| SCHEMBL15367198 | 0.69 | MAPK1 (0.46) | KDM5BPIM1PIM3PIM2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2662357-B1 | BICYCLIC COMPOUNDS OR SALTS THEREOF FOR USE IN THE TREATMENT OF CANCER | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-9273045-B2 | Azabicyclo compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2016-03-01 | — | — | US | disclosed |
| EP-2452940-B1 | AZABICYCLO COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8912181-B2 | Bicyclic compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-12-16 | — | — | US | disclosed |
| US-20140303162-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8779142-B2 | Azabicyclo compound and salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-07-15 | — | — | US | disclosed |
| EP-2662357-A1 | NOVEL BICYCLIC COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2013-11-13 | — | — | EP | disclosed |
| US-20130296320-A1 | NOVEL BICYCLIC COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-11-07 | — | — | US | disclosed |
| CN-102471335-A | Azanebicyclic compound or salt thereof | TAIHO PHARMACEUTICAL CO LTD | 2012-05-23 | — | — | CN | disclosed |
| EP-2452940-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2012-05-16 | — | — | EP | disclosed |
| US-20120108589-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303162-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | HSP90AB1, HSP90AB2P, HSP90AA1 | PDE3B 1933/4885PDE3A 2505/4885PIK3CD 1850/4885 |
| US-20130296320-A1 | NOVEL BICYCLIC COMPOUND OR SALT THEREOF | HSP90AB1, HSP90AA1, HSP90AB2P | PDE3B 1652/4885PDE3A 1952/4885PIK3CD 3026/4885 |
| US-20120108589-A1 | AZABICYCLO COMPOUND AND SALT THEREOF | HSP90AB1, HSP90AB2P, HSP90AA1 | PDE3B 1933/4885PDE3A 2505/4885PIK3CD 1850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.